Issie Kirby

You made an interesting comment at the end around looking at sort of next-generation manufacturing and production. Obviously appreciate it's early, but would love any more color

if I may, on SightGlass and the FDA approval. Any updates there?

any more color you could give us on what particular areas you're looking at? Is it mainly in vision? Is it in surgical or more across the board?

How is my site doing in Asia? And then do you have any update on the Sight Glass approval

any more color about really what's driving the softness in in Asia And then any thoughts on really the consumer or the cyclical risk to IVF demand in The US?

The declines in China, is that just tied to broader macro weaker consumer?

on Sight Glass, would love a little more color on any sort of detail you can give around in the number of units sold in China, the number of children perhaps you are reaching with those products

One of your competitors coming out with a seven day wear lens in 2025. Just wanted to get your thoughts on that category

can you just comment on exactly perhaps give some color on what's really supporting the outperformance there, the share gains

What prompted the redesign? With the international launch, how broad do you expect to go? Is this a product that you could push into markets where you are not currently present

what are you currently seeing with respect to rep productivity? Any sort of increase versus where you expect it to be when you made these changes

the extent to which you're seeing potentially any of these patients coming from competitive switching versus if they are new to the sensor

how we should be thinking around potential accuracy improvements really going after MARD on the glucose monitoring side

did you break out the proportion of new starts in the U.S. coming from type 2

the Malaysia ramp and the extent to which that impacted gross margins at this quarter

is there anything standing out in terms of who is adopting pump therapy in the type 2 cohort earlier